Veröffentlichte Berichte
- Paxlovid (08/01/2024): Effectiveness of nirmatrelvir-ritonavir on severe outcomes of covid-19 in the era of vaccination and omicron: an updated meta-analysis
- Bebtelovimab (12/2022): Current evidence about effectiveness of Bebtelovimab for the treatment of COVID-19
- Evusheld (11/2022) : Advice regarding the purchase of tixagevimab/cilgavimab (Evusheld) for the treatment of Covid-19 in belgium
- Evusheld (11/2022) : Current evidence about effectiveness of Evusheld for COVID-19 prophylaxis
- Veklury (02/2022): Addition to the advice regarding the purchase of remdesivir (Veklury) for the Treatment of covid-19 patients in Belgium
- Paxlovid (06/2022): Addition to the advice regarding the purchase of nirmatrelvir/ritonavir (Paxlovid)
- Evusheld (02/2022): Advice regarding the purchase of tixagevimab/cilgavimab for the prevention of COVID-19 in Belgium
- Xevudy (12/2021): Advice regarding the purchase of sotrovimab (Xevudy)
- Paxlovid (12/2021): Advice regarding the purchase of nirmatrelvir/ritonavir (Paxlovid)
- Veklury (12/2021): Advice regarding the purchase of remdesivir (veklury) for the Treatment of covid-19 patients in Belgium
- Lagevrio (12/2021): Rat bezüglich des Einkaufs von Molnupiravir über eine bilaterale Vereinbarung (in Niederländisch oder in Französisch)